GRCE
NASDAQ
US
Grace Therapeutics, Inc. - Common Stock
$5.13
▲ +$0.25
(+5.12%)
Vol 668K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$53.5M
ROE
-7.4%
Margin
-4435.0%
D/E
0.00
Beta
0.75
52W
$2–$5
Wall Street Consensus
8 analysts · Apr 20262
Strong Buy
5
Buy
1
Hold
0
Sell
0
Strong Sell
87.5%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 100.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.29 | $-0.14 | +$0.15 |
| Sep 2025 | $-0.19 | $-0.06 | +$0.13 |
| Jun 2025 | $-0.22 | $-0.21 | +$0.01 |
| Mar 2025 | $-0.32 | $0.10 | +$0.42 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net Income | — | -$4.2M | $636K | -$3.4M | -$938K | -$2.3M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -16.3% | -16.3% | -16.3% | -16.3% | -7.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -4435.0% | -4435.0% | -4435.0% | -4435.0% | -4435.0% |
| Gross Margin | — | 65.0% | 65.0% | 65.0% | 65.0% | 65.0% |
| D/E Ratio | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | — | 11.77 | 11.77 | 11.77 | 11.77 | 13.89 |
Key Ratios
ROA (TTM)
-6.7%
P/S (TTM)
267.70
P/B
0.3
EPS (TTM)
$-0.59
52W High
$4.69
52W Low
$1.75
$1.75
52-Week Range
$4.69
Financial Health
Free Cash Flow
-$2.2M
Cash
$18.7M
As of Dec 31, 2025
How does GRCE compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
GRCE valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
267.7
▲
5308%
above
peers
(5.0)
vs Peers
vs Industry
Overvalued
P/B ratio
0.4
▼
84%
below
peers
(2.1)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
GRCE profitability vs Pharmaceuticals peers
ROE
-7.4%
▲
86%
above
peers
(-54.3%)
vs Peers
vs Industry
Top tier
Net margin
-4435.0%
▼
9262%
below
peers
(-47.4%)
vs Peers
vs Industry
Weak
Gross margin
65.0%
▼
5%
below
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
-6.7%
▲
82%
above
peers
(-37.4%)
vs Peers
vs Industry
Top tier
GRCE financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(1.5)
vs Peers
vs Industry
Low debt
Current ratio
13.9
▲
314%
above
peers
(3.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.8
▼
20%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
GRCE fundamentals radar
GRCE
Peer median
Industry
GRCE profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
GRCE vs peers: key metrics
Top Holders
Top 5: 25.8%Nantahala Capital Managemen…
8.34%
$5.5M
AIGH Capital Management LLC
6.42%
$4.2M
Adar1 Capital Management, L…
4.54%
$3.0M
Bank of America Corporation
3.50%
$2.3M
Vanguard Group Inc
3.00%
$2.0M
As of Dec 31, 2025
Latest News
No related news yet